NO20061265L - Stabil krystallinsk form av bifeprunoksmesylat (7-[4-([l,l-bifenyl]-3-yl-metyl)-1-piperazinyl]-2(3H)-benzokazolon monometansulfona - Google Patents

Stabil krystallinsk form av bifeprunoksmesylat (7-[4-([l,l-bifenyl]-3-yl-metyl)-1-piperazinyl]-2(3H)-benzokazolon monometansulfona

Info

Publication number
NO20061265L
NO20061265L NO20061265A NO20061265A NO20061265L NO 20061265 L NO20061265 L NO 20061265L NO 20061265 A NO20061265 A NO 20061265A NO 20061265 A NO20061265 A NO 20061265A NO 20061265 L NO20061265 L NO 20061265L
Authority
NO
Norway
Prior art keywords
piperazinyl
biphenyl
monomethanesulfone
benzocazolone
methyl
Prior art date
Application number
NO20061265A
Other languages
English (en)
Norwegian (no)
Inventor
Itene Eijgendaal
Gerrit Klien
Maria J K Terhorst-Van Amstel
Klaas Zwier
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34924088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20061265(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20061265L publication Critical patent/NO20061265L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
NO20061265A 2003-08-18 2006-03-20 Stabil krystallinsk form av bifeprunoksmesylat (7-[4-([l,l-bifenyl]-3-yl-metyl)-1-piperazinyl]-2(3H)-benzokazolon monometansulfona NO20061265L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102573 2003-08-18
PCT/EP2004/051816 WO2005016898A2 (en) 2003-08-18 2004-08-18 Stable polymorph of bifeprunox mesilate

Publications (1)

Publication Number Publication Date
NO20061265L true NO20061265L (no) 2006-05-09

Family

ID=34924088

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061265A NO20061265L (no) 2003-08-18 2006-03-20 Stabil krystallinsk form av bifeprunoksmesylat (7-[4-([l,l-bifenyl]-3-yl-metyl)-1-piperazinyl]-2(3H)-benzokazolon monometansulfona

Country Status (26)

Country Link
EP (1) EP1656358B1 (zh)
JP (1) JP2007502802A (zh)
CN (1) CN100422159C (zh)
AR (1) AR045362A1 (zh)
AT (1) ATE499348T1 (zh)
AU (1) AU2004265104B2 (zh)
BR (1) BRPI0413617A (zh)
CA (1) CA2536149C (zh)
DE (1) DE602004031534D1 (zh)
DK (1) DK1656358T3 (zh)
EA (1) EA008182B1 (zh)
ES (1) ES2361508T3 (zh)
IS (1) IS8279A (zh)
ME (1) MEP37108A (zh)
MX (1) MXPA06001881A (zh)
MY (1) MY139462A (zh)
NO (1) NO20061265L (zh)
NZ (1) NZ545415A (zh)
PL (1) PL1656358T3 (zh)
PT (1) PT1656358E (zh)
RS (1) RS20060113A (zh)
SI (1) SI1656358T1 (zh)
TW (1) TWI336695B (zh)
UA (1) UA85562C2 (zh)
WO (1) WO2005016898A2 (zh)
ZA (1) ZA200601399B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423040B2 (en) * 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
CA2654557A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and l-dopa
BRPI0715445A2 (pt) 2006-08-31 2014-05-13 Solvay Pharm Bv Uso de um composto de bifeprunox, e, kit de titulação
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
US9556916B2 (en) 2013-03-15 2017-01-31 Whirlpool Corporation High performance adjustable juicer with whole foods feed chute and clutch mechanism
US9675101B2 (en) 2013-03-15 2017-06-13 Whirlpool Corporation High performance adjustable juicer with whole foods feed chute

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2250347C (en) * 1996-03-29 2006-02-21 Duphar International Research B.V. Piperazine and piperidine compounds with high affinity for dopamine-d2 and serotonin-5ht1a receptors
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
AU2003999A (en) * 1997-12-19 1999-07-12 Advanced Research And Technology Institute, Inc. Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof
AR034206A1 (es) * 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos

Also Published As

Publication number Publication date
CN1835935A (zh) 2006-09-20
TW200513462A (en) 2005-04-16
ZA200601399B (en) 2007-04-25
RS20060113A (en) 2008-09-29
CN100422159C (zh) 2008-10-01
MXPA06001881A (es) 2006-05-17
SI1656358T1 (sl) 2011-06-30
EP1656358B1 (en) 2011-02-23
DE602004031534D1 (de) 2011-04-07
ATE499348T1 (de) 2011-03-15
UA85562C2 (en) 2009-02-10
BRPI0413617A (pt) 2006-10-17
AR045362A1 (es) 2005-10-26
AU2004265104A1 (en) 2005-02-24
CA2536149A1 (en) 2005-02-24
EA200600442A1 (ru) 2006-08-25
AU2004265104B2 (en) 2009-06-04
PT1656358E (pt) 2011-05-12
ES2361508T3 (es) 2011-06-17
WO2005016898A3 (en) 2005-04-07
MEP37108A (en) 2011-02-10
EA008182B1 (ru) 2007-04-27
MY139462A (en) 2009-10-30
IS8279A (is) 2006-01-31
DK1656358T3 (da) 2011-05-30
TWI336695B (en) 2011-02-01
WO2005016898B1 (en) 2005-05-19
PL1656358T3 (pl) 2011-07-29
NZ545415A (en) 2009-11-27
JP2007502802A (ja) 2007-02-15
CA2536149C (en) 2011-03-22
WO2005016898A2 (en) 2005-02-24
EP1656358A2 (en) 2006-05-17

Similar Documents

Publication Publication Date Title
NO20061265L (no) Stabil krystallinsk form av bifeprunoksmesylat (7-[4-([l,l-bifenyl]-3-yl-metyl)-1-piperazinyl]-2(3H)-benzokazolon monometansulfona
NO20061151L (no) Succinat- og malonatsalt av trans-4-((ir,3s)-6-klor-3-fenylindan-i-yl)-1,2,2-trimetylpiperazin og anvendelsen som et medikament
ATE517884T1 (de) 3,4-dihalobenzylpiperidinderivate und deren medizinische verwendung
ATE378332T1 (de) Benzofuranderivate,verfahren zu deren herstellung und zwischenprodukte davon
MXPA04006003A (es) Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano.
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
WO2003004480A3 (en) Substituted piperazine and diazepanes as histamine h3 receptor agonists
NO20073465L (no) Benzotiazol-derivater
MY128051A (en) Mesylate trihydrate salt of 5-(2-(4-(1, 2-benzisothiazol-3 -yl)-1-piperazinyl)ethyl)-6-chloro-1, 3-dihydro-2-(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
HK1062888A1 (en) Vinyl phenyl derivatives as glk activators
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
NO20065060L (no) Farmasoytiske kombinasjoner inneholdende benzoksazin for behandling av respiratoriske forstyrrelser
HUP0401201A2 (hu) Flibanserin stabil polimorfja, ipari eljárás előállítására és alkalmazása gyógyszerek előállítására
CA2252898A1 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist
NO20052699L (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
MA46268A (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
HUP0204520A2 (en) Pharmaceutical composition containing esmolol and process for its preparation
ATE410148T1 (de) Pharmazeutische zubereitung zur oralen verwendung von heparin und seinen derivaten
AR004378A1 (es) Utilizacion de los derivados de 1-{4-(4-aril(o heteroaril)-1-piperazinil)- butil}-1h-azol para la preparacion de un medicamento destinado al tratamientode los trastornos obsesivo-compulsivos, la apnea del sueno, las disfunciones sexuales, la emesis y el mareo en los mamiferos, incluido el hombre.
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
AU2003232805A8 (en) Pharmaceutical active substance combination and the use thereof
CL2008003066A1 (es) Compuestos derivados de 1-[3-(fenilamino)-5-(piridin-4-il)-1h-1,2,4-triazol-1-il]-alquil-2-ol; composición farmacéutica; procedimiento de preparación de dicha composición; y uso para el tratamiento o prevención de una enfermedad del sistema nervioso central.
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
FR2642758B1 (fr) Derives de pyrimidine,2-(4-((alpha)-heteroaryl-(alpha) aryl-((alpha)-alkyl)-methoxy)-butyl)-1-piperazinyl), avec activite serotoninergique

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application